23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021. The new year saw the company announcing its diversification into drug development.

23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?

GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using  23andMe's proprietary genetic and health survey database

23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redemption (the “Redemption”) of all of its outstanding warrants (the “Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent. The Warrants include the public warrants (the “Public Warrants”) issued as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and the private warrants that were sold in a private placement simultaneously with the IPO.

23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants

Medpace Holdings

Mesa Laboratories

These smaller healthcare companies all have 10x potential for investors.

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

GlaxoSmithKline

These two companies have massive growth opportunities and have declined sharply in recent months.

2 Cheap Stocks With 10X Potential to Buy in 2022

Airbnb

Legalzoom.com

3 Top IPO Stocks to Put on Your Watchlist

Poshmark

Riskified Ltd

With these kinds of resources, these companies are becoming less-risky investments.

Like Strong Balance Sheets? These 3 Stocks Are Loaded With Cash

The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks.

Why 23andMe Stock Dropped 29% in November

Her genetics testing company is the latest to flounder after going public via SPAC.

Anne Wojcicki's 23andMe Fortune Falls Under $1 Billion As Shares Sink Post-IPO

Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team

23andMe Announces the Appointment of Joseph R. Arron, M.D.

SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and that remain outstanding at 5:00 p.m. New York City time on December 22, 2021 (the “Redemption Date”) for a redemption price of $0.10 per Public Warrant. In addition, 23andMe will redeem all of its outstanding warrants to purchase Class A common stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO (the “Private Warrants” and, together with the Public Warrants, the “Warrants”) on the same terms as the outstanding Public Warrants.

23andMe Announces Redemption of All Outstanding Warrants

23andMe recently reported quarterly results which held no major surprises as the company continues to build out its DNA-based reports available to consumers.

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Last week's good news for the genetic data miner wasn't as good as it looked.

Why 23andMe Stock Crashed 10% Today

23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?

Why 23andMe Stock Scored an 11% Gain Today

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q2 2021 Results - Earnings Call Transcript

Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives

23andMe Reports FY2022 Second Quarter Financial Results

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at three upcoming virtual investor conferences: Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11 at 12:10 pm ET Piper Sandler 33rd Annual Healthcare Conference.

23andMe to Present at Upcoming Virtual Healthcare Conferences

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors.

23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors

Coinbase

Plug Power

Nearly 500 companies are reporting quarterly earnings this week. The one in our watch list for Monday morning, Coty, beat estimates on both the top and bottom lines.

Earnings Previews: Coinbase, Nio, Plug Power, 23andMe

SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021.

23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders

The genetics upstart is acquiring a telehealth platform.

Why 23andMe Rocketed 27.9% Higher in October

SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health”), an on-demand platform for accessing medical care and pharmacy services online.

23andMe Announces the Closing of its Acquisition of Lemonaid Health

Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid.

News for 23andMe Stock (ME)